PTCT vs SPRB
PTCT: PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved products and partnered collaboration deals. SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | PTCT | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $78.40 | $44.60 | |
| Market cap as of 2026-07-23 | $6.5B | $123M | |
| P/E as of 2026-07-23 | 881.48 | n/a | |
| PEG as of 2026-07-23 | 1.20 | n/a | |
| Net margin as of 2026-07-23 | +0.9% | -1079.9% | PTCT higher |
| Gross margin as of 2026-07-23 | +32.6% | n/a | |
| Operating margin as of 2026-07-23 | +8.9% | -1143.4% | PTCT higher |
| ROE as of 2026-07-23 | +0.1% | -155.4% | PTCT higher |
| ROA as of 2026-07-23 | +0.3% | -101.7% | PTCT higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.19 | PTCT lower |
| Revenue growth (YoY) as of 2026-07-23 | -53.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +35.3% | n/a | |
| Beta as of 2026-07-23 | 0.54 | 3.45 | |
| 1-year return as of 2026-07-22 close | +69.0% | +423.9% | SPRB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.